Alexion's follow-on stacks up to Soliris

The biotech's successor candidate, ALXN1210, demonstrated non-inferiority to the blockbuster drug in a study of patients with PNH.

By Lisa LaMotta • March 15, 2018

Incyte study could bring lessons for cancer immunotherapy

Merck has bet on the potential of Incyte's IDO blocker as a partner for Keytruda across five different cancer types. A Phase 3 trial in melanoma is first up.

By Ned Pagliarulo • March 14, 2018

Explore the Trendline➔

Neuroscience drug development

Enthusiasm is running higher among drugmakers and investors for neuroscience drug development, buoyed by recent approvals of new Alzheimer’s, ALS and depression medicines.

By BioPharma Dive staff

Right to Try fails amid warning from regulators, patient groups

Backers of the bill like President Trump and the Koch brothers faced off against major patient groups and some regulators.

By David Lim • March 14, 2018

Positive readout for AbbVie's second fibroids Phase 3

AbbVie's elagolix met its primary endpoints in its second late-stage study of women with uterine fibroids.

By Suzanne Elvidge • March 14, 2018

Anthera shares plunge as company drops failed CF drug

Shares in the biotech moved toward an all-time low on news of its Phase 3 miss in CF, which led the company to discontinue development of Sollpura.

By Suzanne Elvidge • March 13, 2018

Biogen snaps up Pfizer's schizophrenia candidate

Sale of the experimental drug to Biogen comes two months after Pfizer announced plans to end its early-stage neuroscience research.

By Randi Hernandez • March 12, 2018

AstraZeneca pushes back readout of key lung cancer study

The pharma is counting on overall survival results from its crucial MYSTIC study of Imfinzi plus tremelimumab to redeem a damaging setback last year.

By Ned Pagliarulo • March 12, 2018

J&J's CANVAS study positive, pitting Invokana against Jardiance

The SGLT-2 inhibitor improved cardiovascular outcomes for people who have type 2 diabetes, setting it up to better compete with Eli Lilly and Boehringer Ingelheim's rival drug.

By Suzanne Elvidge • March 12, 2018

Regeneron-Sanofi cholesterol drug cuts heart risk in major study

In an unusual step, the companies signaled willingness to lower the price of Praluent if insurers ease restrictions that have so far limited uptake.

By Ned Pagliarulo • March 10, 2018

Prescribed Reading: Bold comments from Gottlieb, PBMs get the spotlight

Against the backdrop of Cigna's planned deal to buy Express Scripts, the FDA chief sharply criticized bad behavior from players involved in drug pricing.

By Lisa LaMotta • March 9, 2018

Despite crowded I/O field, pharma, VCs still eager to invest

Surging biopharma investment into cancer has raised concerns about duplicative research. Industry execs, however, see the opportunities as too great to pass up.

By Ned Pagliarulo • March 9, 2018

VBL brain cancer drug flunks Phase 3

The Israeli biotech saw its stock drop more than 60% on the late-stage failure. 

By Lisa LaMotta • March 8, 2018

Merck partners with Eisai in sweeping bet on Keytruda combo

Eisai will receive a sizable $300 million upfront, but the real value of the deal will come if studies testing its drug Lenvima together with Keytruda bear fruit.

By Ned Pagliarulo • March 8, 2018

Merck KGaA's BTK drug hits in Phase 2 MS study

Treatment with evobrutinib significantly reduced lesions characteristic of the disease compared to placebo.

By Jacob Bell • March 8, 2018

Despite positive data, Esperion still has high hurdle to clear

The biotech reported strong results for its cholesterol-lowering drug, but faces a crowded market that isn't welcoming to new treatments.

By Jacob Bell • March 7, 2018

Gilead builds case for switching to its new HIV triplet

New data are demonstrating that HIV-positive women can swap Genvoya, Stribild and other therapies for Biktarvy and experience similar benefits.

By Jacob Bell • March 6, 2018

Santhera shares slide as Raxone fails in MS study

Results from the small NIH study showed no difference between patients given Raxone versus placebo on a measure of disease progression. 

By Ned Pagliarulo • March 5, 2018

What you need to know about the microbiome

Research into the clinical applications of the microbiome is gathering steam, spurring new investment and raising hopes for novel therapeutics.

By Lisa LaMotta • March 5, 2018

Dermira acne drug misses the mark, surprising investors

In two Phase 3 trials, DRM01 failed to meet any of its study objectives, pushing the biotech to discontinue further development of the drug.

By Ned Pagliarulo • March 5, 2018

Positive data pushes G1 to speed up development of its CDK inhibitor

Treatment with trilaciclib significantly improved immune system function for small cell lung cancer patients, building a stronger profile for G1's main drug.

By Jacob Bell • March 5, 2018

Shire's HAE candidate boosted by new Phase 3 data

The FDA is expected to decide on approval of lanadelumab by August, potentially adding to Shire's existing HAE portfolio.

By Suzanne Elvidge • March 5, 2018

Roche, Ionis showcase potential of Huntington's disease drug

Early data suggest Ionis' candidate, which Roche paid $45 million to license, could lower levels of a mutant protein responsible for driving the disease.

By Ned Pagliarulo • March 2, 2018

Verona lifted as main asset shows promise in CF

Shares of the U.K.-based biotech rose more than 25% after its drug, RPL554, significantly improved patients' lung function in a small Phase 2 study.

By Jacob Bell • March 2, 2018

Prescribed Reading: Sketchy subgroup analyses, puzzling probes

Several companies used creative thinking when evaluating clinical trial results, while others played the game of excluding details when informing investors.

By Lisa LaMotta • March 2, 2018

DBV reveals cloudy results for milk allergy patch

Despite unclear results from a mid-stage trial, the French biotech touted positive data from a subpopulation of patients in the milk allergy study.

By Lisa LaMotta • Feb. 27, 2018